The 2025 European Society for Medical Oncology (ESMO) Congress was held from October 17 to 21 in Berlin, Germany, in a hybrid format that combined online and in-person participation. The latest research findings from the team led by Professor Zhang Xing at Sun Yat-sen University Cancer Center were presented in an oral session at the ESMO Congress. This is a single-arm, open-label, multicenter Phase II clinical trial evaluating Chidamide in combination with toripalimab for the treatment of advanced soft-tissue sarcoma. The data presented showed an objective response rate (ORR) of 30.4%, a disease control rate (DCR) of 73.9%, and a median progression-free survival (mPFS) of 7.1 months. Notably, significant efficacy was observed in the well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS) subtype, which has traditionally shown limited sensitivity to chemotherapy and immunotherapy, with an ORR of 62.5% and mPFS of 17.1 months. These results suggest that chidamide combined with toripalimab offers a new treatment option for patients with advanced soft tissue sarcoma who have no standard of care (SOC) or have failed prior SOCs, particularly for those with WDLPS/DDLPS, and holds promise as an important future strategy for treating such diseases.